1. Academic Validation
  2. Bakuchicin attenuates atopic skin inflammation

Bakuchicin attenuates atopic skin inflammation

  • Biomed Pharmacother. 2020 Sep:129:110466. doi: 10.1016/j.biopha.2020.110466.
Jae-Sung Lim 1 Jun Young Kim 2 Soyoung Lee 3 Jin Kyeong Choi 4 Eun-Nam Kim 5 Young-Ae Choi 1 Yong Hyun Jang 6 Gil-Saeng Jeong 7 Sang-Hyun Kim 8
Affiliations

Affiliations

  • 1 Cell & Matrix Research Institute, Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • 2 Department of Dermatology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • 3 Immunoregulatory Materials Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea.
  • 4 Department of Immunology, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
  • 5 College of Pharmacy, Keimyung University, Daegu, Republic of Korea.
  • 6 Department of Dermatology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. Electronic address: yhjang@knu.ac.kr.
  • 7 College of Pharmacy, Keimyung University, Daegu, Republic of Korea. Electronic address: gsjeong@kmu.ac.kr.
  • 8 Cell & Matrix Research Institute, Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea. Electronic address: shkim72@knu.ac.kr.
Abstract

Psoralea corylifolia is a medicinal herb that provides advantageous pharmacological effects against vitiligo and skin rash. Former studies have shown that bakuchicin, a furanocoumarin compound from the fruits of P. corylifolia, has therapeutic effects against inflammation, and Infection. This study aimed to define the pharmacological effects of bakuchicin on inflammatory responses and lichenification, the major symptoms of atopic dermatitis (AD). To induce AD-like skin inflammation, we exposed the ears of female BALB/c mice to 2, 4-dinitrochlorobenzene (DNCB) and Dermatophagoides farinae (house dust Mite) extract (DFE) for 4 weeks. Intragastric administration of bakuchicin attenuated the symptoms of AD-like skin inflammation, as evident by reductions in ear thickness, erythema, and keratosis. Bakuchicin also reversed increases in auricular epidermal and dermal layer thicknesses, and attenuated eosinophil and mast cell infiltration in AD-induced mice. It also suppressed Th2 gene expression as well as that of pro-inflammatory cytokines and chemokines, such as interleukin (IL)-4, IL-13, IL-31, IL-1β, IL-6, CXCL-1, and CCL-17 in the ear tissue. The levels of total and DFE-specific immunoglobulin (Ig)E, and IgG2A in the mice sera were reduced by the bakuchicin. To investigate the effect of bakuchicin on keratinocytes, experiments were performed using HaCaT cells, the representative cell type used in skin disease studies. Tumor necrosis factor-α and interferon-γ were used to activate keratinocytes. Bakuchicin suppressed Th2 gene expression and that of pro-inflammatory cytokines and chemokines; it also suppressed STAT-1 phosphorylation and the nuclear translocation of NF-κB in activated keratinocytes. These results suggest that bakuchicin attenuated AD symptoms, thus suggesting it as a potential therapeutic agent for the treatment of AD.

Keywords

Atopic dermatitis; Bakuchicin; Eosinophils; Keratinocytes.

Figures
Products